zbjornson

Rather, "there is no evidence to show that using insecticide to kill mosquitoes inside aircraft cabins is effective in preventing introduction and spread of mosquito-borne diseases."

https://www.epa.gov/mosquitocontrol/aircraft-disinsection

Not sure where the idea came from that spraying the cabin aisle would penetrate the luggage bins, cargo hold, under the seats, or really anywhere.

"Google Fi users are not subject to T-Mobile's collection and sale of app data." From the first expandable question on https://support.google.com/fi/answer/6181037?hl=en#zippy=%2C....

SEEKING FREELANCER | UTC-4 to UTC-9 ish | Remote

Seeking a web test automation engineer with in-depth knowledge of Cypress, Mocha and API testing (Supertest) (all JavaScript/TypeScript). Prefer knowledge of fuzzing, nice to have knowledge of property-based testing. We're building a life science research SaaS product that's used in regulated industries; testing supports our validation process.

my username at primitybio dot com

Quite a letdown that the solution for a web-based spreadsheet is for users to install a local backend. Might be a case for edge computing even.

> WebAssembly has a single contiguous, linear memory space shared by all dynamic memory allocations. This means that WASM cannot make use of several memory management features that operating systems provide, such as Virtual Memory, Swapping, etc. Additionally, it cannot make use of the CPU’s MMU optimisations such as prefetching and caching.

WebAssembly has memory issues, but those are not them. Virtual memory and swapping are OS features that work at the page level. CPU prefetching and caching are CPU features that work at the cacheline/address level. [1] covers the major design limitations with WebAssembly memory.

[1] https://github.com/WebAssembly/design/issues/1397

California residents, here's the data deletion form: https://consumer.risk.lexisnexis.com/request#california

It turns out that collision among egg farmers is likely the actual cause of rising egg prices -- not avian flu or CA's new cage law. https://modernfarmer.com/2023/01/record-breaking-egg-profits...

This is not quite right. I don't think any other pharmacy tests what they dispense. It's expensive, difficult, and the FDA doesn't seem to appreciate that their risk management strategy is being second-guessed. They recently issued a long warning letter to Valisure for doing it [0].

Note that ValisureRx (consumer pharmacy that dispensed lot-tested drugs) was sold to Medley Pharmacy, which just folded. Valisure is now just a testing lab.

Finally, it's not just a chain of custody thing. Even big generic brands and name-brands source a huge amount of active pharmaceutical ingredients (APIs) from China and India.

[0] https://www.fda.gov/media/163682/download

It's been built-in since December to Google Workspace premium tiers:

https://workspaceupdates.googleblog.com/2022/12/format-displ...

Medical appointment reminders and other medical communications have a special cutout in the TCPA, including reduced consent requirements. They annoy me too though; they're redundant with my calendar reminders. The feedback SMS might not be included in the exception either.

https://blog.curogram.com/what-are-tcpa-and-traced-act-and-h...

"Virtual kitchens" (ghost kitchens) are encouraged by doordash as a way to diversify and boost revenue and stuff:

https://get.doordash.com/en-us/blog/virtual-restaurant-brand

They seem to be used frequently as decoys to allow restaurants to drop bad reviews though.

On the contrary, it could be easily mistaken for herpes, molluscum, warts, syphilis, acne, insect bites... This outbreak doesn't usually have the severe rash that's characteristic of classic monkeypox.

CellCarta (formerly Primity Bio) | USA and Canada | Senior Front-End or Full-Stack Dev | Remote

Our team builds a high-performance bioinformatics data analysis SaaS application that researchers use to analyze millions of single cells and create visualizations for drug development, clinical trials and more. (Landing page: https://cellengine.com.)

We're seeking a senior front-end or full-stack developer to join our team. No experience in biology needed. Ideally you have a passion for building interactive UIs, excellent fundamental HTML and CSS skills, in-depth experience with a UI framework (we use Vue, but any component-based framework is okay) and keen attention to detail. Opportunities exist to contribute to open-source projects.

Our dev team is small, close-knit and spread around the US and Europe. We're situated within a larger contract research organization (CRO) that provides research services, headquartered in Montreal.

contact: zbjornson at primitybio.com (CellEngine team lead)

They did. We got personalized emails for each account showing the effect on each project.

I feel the opposite. Everything I've used in GCP, I've understood and appreciated the design decisions behind. Most things I've used in AWS, I've wondered why they shipped it that way. Examples:

* High-availability HSM KMS: trivial in GCP, super difficult in AWS.

* Object storage (GCS/S3): multi-region is trivial in GCP, somewhat harder in AWS. Archival is so much simpler in GCS than S3 Glacier.

* IAM: makes sense to me in GCP and is consistent across products, AWS policy editor has poor usability and feels inconsistent between products.

* Having per-region pages in the AWS console is a pain, easy to lose stuff. GCP is one global interface.

* Cloud functions/Lambda: CF Just Work with native dependencies. Lambda is painful in that regard.

GCP's auth lib is confusing though, I agree with you there. We stopped using it and all of their client libs a few years ago and wrote our own. However, that they force you to use service accounts is an excellent security decision.

This is an intervention study, not a double-blind, placebo-controlled RCT. Patients knew they were getting ivermectin and the control group knew they weren't. With an effect that small (1.2% vs 2.0%, p=0.024) and only in >40 year-olds, bias/placebo effect seems very possibly confounding.

They're showing inhibition at 100 ug/ml, but it looks like high doses result in serum CBDA concentrations in the low 100s of ng/ml [1].

[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498943/

CRCs have the awesome ability to be composed, and are many times faster to compute than SHAs with the best hardware acceleration.

PerfkitBenchmarker has a boot timer like this (time to SSH) that works for all major cloud providers.

https://github.com/GoogleCloudPlatform/PerfKitBenchmarker

You could pad the input as you said, which avoids a "tail loop," but otherwise you usually do a partial load (load <8 elements into a vector) and store. Some instruction set extensions provide "masked load/store" instructions for this, but there are ways to do it without those too.

To your last question specifically, if you _mm256_load_ps(&ys[i]) and you're at the edge of a page, you'll get a segfault. Otherwise you'll get undefined values (which can be okay, you could ignore them instead of dealing with a partial load).

Shameless plug: I made bson-to-json for more or less the same purpose with MongoDB: converting the raw BSON response from the DB directly to JSON strings. Saves lots of CPU cycles and GC pressure.

https://github.com/zbjornson/bson-to-json

We have no idea how many drugs would work in humans but are not being considered because they don't work in animals. If we assume it's about the same as the number that work in animals but don't work in humans, we're missing out on a huge number of therapies.

CellCarta (formerly Primity Bio) | USA and Canada | Senior Front-End Dev | Remote

Our team builds a high-performance bioinformatics data analysis SaaS application that researchers use to analyze millions of single cells and create visualizations for drug development, clinical trials and more. (Landing page: https://cellengine.com.)

We're seeking a senior front-end developer to join our team. No experience in biology needed. Ideally you have a passion for building interactive UIs, excellent fundamental HTML and CSS skills, in-depth experience with a UI framework (we use Vue, but any component-based framework is okay) and keen attention to detail. Opportunities exist to contribute to open-source projects.

Our dev team is small, close-knit and spread around the US and Europe. We're situated within a larger contract research organization (CRO) that provides research services, headquartered in Montreal.

contact: zbjornson at primitybio.com (CellEngine team lead)

CellCarta (formerly Primity Bio) | USA and Canada | Senior Front-End Dev | Remote

Our team builds a high-performance bioinformatics data analysis SaaS application that researchers use to analyze millions of single cells and create visualizations for drug development, clinical trials and more. (Advertising page: https://cellcarta.com/cellenginesoftware/.)

We're seeking a senior front-end developer to join our team. No experience in biology needed. Ideally you have excellent fundamental HTML and CSS skills, in-depth experience with a UI framework (we use Vue, but any component-based framework is okay) and keen attention to detail. Opportunities exist to contribute to open-source projects.

Our dev team is small, close-knit and spread around the US and Europe. We're situated within a larger contract research organization (CRO) that provides research services, headquartered in Montreal.

contact: zbjornson at primitybio.com (CellEngine team lead)

FTA: "This post aimed to cover a scenario where the cost of compression, in both compute resource and time-to-build, was significantly outweighed by the savings it would make."

Moderna's phase 3 includes preliminary data on a single dose, and it appears 80-90% effective at/after two weeks. See table 15 on page 28:

https://www.fda.gov/media/144434/download

https://www.wbur.org/commonhealth/2020/12/18/coronavirus-vac...

That approach is called heterologous prime-boost, and it's likely being tested for the Oxford/AstraZeneca + Pfizer combo and the Oxford/AstraZeneca + Sputnik V combo to try to increase potency (not to increase supply). It's not being tested for the combo of the two mRNA vaccines (Pfizer/BioNTech and Moderna) though.

You quoted the worst of the four models that they evaluated ("This model was the least parsimonious model we evaluated"), and only part of that model even. They're not pushing that sole hypothesis; they were testing to see if that could explain the current evidence.

The other models they tested were better:

> First, we modelled increased infectiousness as an increase in the risk of transmission of VOC 202012/01 per contact, relative to preexisting variants. This model was best able to capture the data parsimoniously among the four hypotheses tested...

He mentions this doesn't work with RIP-relative addressing, but I don't see how it would cause a penalty otherwise.

Tip: You can turn that off!

Hamburger menu > settings > ask to open app

There's no reason to expect any parallels between variolation with these two unrelated viruses.